Methylphenidate, cognition, and epilepsy: A 1-month open-label trial

Area of Science:

• Neurology
• Neuroscience
• Clinical Pharmacology

Background:

• Cognitive deficits are prevalent in epilepsy patients, with limited treatment options beyond seizure control.
• Methylphenidate is effective for attention-deficit/hyperactivity disorder in children with epilepsy, but its efficacy in adults remains under-evaluated.

Purpose of the Study:

• To evaluate the safety and efficacy of methylphenidate in improving cognitive function in adults with epilepsy.
• To assess the impact of methylphenidate on quality of life and seizure frequency in this population.

Main Methods:

• An open-label, 1-month trial of methylphenidate (20-40 mg/day) following a double-blind, placebo-controlled phase.
• Cognitive assessments included the Symbol-Digit Modalities Test (SDMT), Conners' Continuous Performance Test (CPT), and Medical College of Georgia Memory Test (MCG).
• Secondary measures included mood, anxiety, apathy, side effects, quality of life (QOLIE-89), and seizure frequency, with 14 healthy controls for comparison.

Main Results:

• Significant improvements were observed in SDMT, MCG, CPT performance (discriminating targets, reaction time variability, omissions, commissions), and QOLIE-89 subscales (energy, attention, memory, language).
• Moderate to large effect sizes were noted for cognitive improvements.
• Methylphenidate treatment did not increase seizure frequency (mean 2.8/month at baseline vs. 2.4/month post-treatment).

Conclusions:

• Methylphenidate appears to be a safe and effective option for enhancing cognition and quality of life in adults with epilepsy.
• Further large-scale, longer-term double-blind, placebo-controlled trials are warranted to confirm these findings.